Prexton
Prexton a biotech focused on developing novel treatments for the debilitating symptoms of late-stage Parkinson’s disease.
The company was acquired by Lundbeck in March 2018.
Prexton a biotech focused on developing novel treatments for the debilitating symptoms of late-stage Parkinson’s disease.
The company was acquired by Lundbeck in March 2018.